NEW YORK – AstraZeneca has selected an autologous T-regulator (Treg) cell therapy candidate from Quell Therapeutics' pipeline to advance into preclinical and clinical trials in type 1 diabetes, ...
Eight NHS cancer centers will examine tumors from patients with exceptional survival times, focusing on three aggressive cancer types.
Following this update, the company's stock price dropped more than 30 percent from market close Friday to $23.79 per share Monday morning.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback